K. C. Nicolaou et al. / Tetrahedron Letters 52 (2011) 2041–2043
2043
of the methyl ethers (BBr3, CH2Cl2). Although compounds 12–16
likely exist as enantiomeric atropisomers stable at room tempera-
ture, no chiral HPLC separation was undertaken prior to their test-
ing due to the potency equivalence of the two marinopyrrole A
enantiomers (see Table 1, entries 2 and 3).1
presence of human serum, suggesting utility in topical but not
systemic formulations. Further structural modifications, including
the design of prodrug-like compounds, may be necessary in order
to improve the pharmacological profile of the marinopyrroles.
The synthesized compounds [( )-1, (+)-1, (À)-1, ( )-10, and 11–
16] were evaluated for their antibacterial activities against
TCH1516, a strain representative of the current epidemic clone of
community-acquired MRSA.5 The results are shown in Table 1.
Thus, synthetic racemic [( )-1] and enantiopure [(+)-1 and (À)-1]
marinopyrroles (entries 1–3) exhibited antibacterial potencies
comparable to those of their naturally-derived counterparts.1
Interestingly, the tetrabrominated congener of marinopyrrole A
13 (entry 8) exhibited comparable potency to marinopyrrole A,
while the dehalogenated analog 11 (entry 6) was significantly less
active, indicating the importance of the halogen atoms for biolog-
ical activity. It was also clear that the free phenolic groups were
necessary for activity since dimethylated marinopyrrole deriva-
tives [9, ( )-10, and 12] showed no activity (entries 4, 5, and 7,
respectively). Bis-acetylated marinopyrrole 14 (entry 9) showed
similar antibacterial potency to marinopyrrole [( )-1] itself, possi-
bly due to in situ ester hydrolysis within the cell. Excision of one of
the two phenolic rings from the marinopyrrole structure led to ac-
tive, but less potent analogs, as demonstrated by compounds 15
and 16 (entries 10 and 11, respectively). When these compounds
were tested in the same assay, but in the presence of 20% normal
pooled human serum, they were found to lose antibacterial
activity, presumably due to protein adsorption.
Acknowledgments
Financial support for this work was provided by The Skaggs
Institute for Chemical Biology, a National Institutes of Health
(U.S.A.) grant and Ruth L. Kirschstein National Research Service
Award (NRSA) (to N.M.H.), and a National Science Foundation grad-
uate fellowship (to N.L.S.).
Supplementary data
Supplementary data associated (further experimental details
for the synthesis and biological evaluation of compounds as well
as selected physical properties of compounds) with this article
References and notes
1. Hughes, C. C.; Prieto-Davo, A.; Jensen, P. R.; Fenical, W. Org. Lett. 2008, 10,
629.
2. Hughes, C. C.; Kauffman, C. A.; Jensen, P. R.; Fenical, W. J. Org. Chem. 2010, 75,
3240.
3. Hughes, C. C.; Yang, Y.-L.; Liu, W.-T.; Dorrestein, P. C.; La Clair, J. J.; Fenical, W. J.
Am. Chem. Soc. 2009, 131, 12094.
4. Cheng, C.; Pan, L.; Chen, Y.; Song, H.; Qin, Y.; Li, R. J. Comb. Chem. 2010, 12, 541.
5. Haste, N. M.; Hughes, C. C.; Tran, D. N.; Fenical, W.; Jensen, P. R.; Nizet, V.;
Hensler, M. E. Antimicrob. Agents Chemother., submitted for publication.
6. Furneaux, R. H.; Tyler, P. C. J. Org. Chem. 1999, 64, 8411.
7. Rochais, C.; Lisowski, V.; Dallemagne, P.; Rault, S. Bioorg. Med. Chem. 2006, 14,
8162.
In summary, a concise total synthesis of marinopyrrole A (1)
that allows for large scale preparation of this novel natural product
and its analogs is reported. The synthesized compounds were eval-
uated for activity against the clinically-important USA 300 clone of
MRSA, with several showing strong antibacterial potencies. How-
ever, all suffered complete loss of antibacterial activity in the
8. Kikuchi, H.; Sekiya, M.; Katou, Y.; Ueda, K.; Kabeya, T.; Kurata, S.; Oshima, Y. Org.
Lett. 2009, 11, 1693.